| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.06 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | -0.07 | 0.06 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.06 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.065 | 0.06 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.29 | 0.06 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.06 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.06 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.06 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.06 |